Tyagi, A.; Kumar, V.; Giri, R. Assessment of Efficacy and Safety of Daclatasvir, Sofusbuvir and Ribavirin Regimen for 12 Weeks As Compared to Daclatasvir and Sofusbuvir Combination Regimen for 24 Weeks in Decompensated Cirrhotic Patients Due to Hepatitis C Virus Genotype 3 Infection. Int J Adv Med 2022, 9, 636-641.